We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+25.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$288M
AUM Growth
+$45.4M
Cap. Flow
+$18.1M
Cap. Flow %
6.29%
Top 10 Hldgs %
61.77%
Holding
53
New
11
Increased
10
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.63M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.58M
3
HROW icon
Harrow
HROW
+$5.15M
4
KALV
KalVista Pharmaceuticals
KALV
+$4.95M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$4.3M

Top Sells

Rank Stock Value
1
CUTR
Cutera, Inc.
CUTR
+$6.74M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.25M
3
MRUS
Merus
MRUS
+$5.07M
4
KROS icon
Keros Therapeutics
KROS
+$3.89M
5
MRSN
Mersana Therapeutics
MRSN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$55.7M 19.38%
3,775,000
+431,183
+13% +$5.15M
TELA icon
2
TELA Bio
TELA
$29.2M
$23.8M 8.29%
2,072,813
+36,262
+2% +$325K
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.75B
$21.4M 7.44%
735,000
-75,000
-9% -$1.93M
OCUL icon
4
Ocular Therapeutix
OCUL
$2.38B
$17.1M 5.94%
6,075,000
-390,000
-6% -$1.29M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$13.4M 4.66%
732,000
+60,700
+9% +$1.07M
CYTK icon
6
Cytokinetics
CYTK
$10.8B
$11.5M 3.98%
250,000
-13,000
-5% -$559K
KROS icon
7
Keros Therapeutics
KROS
$223M
$11.4M 3.97%
238,000
-83,300
-26% -$3.89M
PCVX icon
8
Vaxcyte
PCVX
$9.1B
$8.49M 2.95%
177,000
-13,000
-7% -$510K
BHVN icon
9
Biohaven
BHVN
$2.43B
$7.5M 2.61%
+540,000
New +$7.63M
FDMT icon
10
4D Molecular Therapeutics
FDMT
$824M
$7.33M 2.55%
330,000
-20,700
-6% -$320K
TARA icon
11
Protara Therapeutics
TARA
$236M
$7.22M 2.51%
2,692,594
-15,473
-0.6% -$48.8K
TCON
12
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$6.84M 2.38%
229,500
+20,000
+10% +$605K
LRMR icon
13
Larimar Therapeutics
LRMR
$421M
$6.44M 2.24%
1,560,000
-101,784
-6% -$347K
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$6.24M 2.17%
+923,200
New +$4.95M
ETON icon
15
Eton Pharmaceutcials
ETON
$1.79B
$6.12M 2.13%
2,170,000
-351,000
-14% -$944K
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.8B
$5.47M 1.9%
611,400
-23,600
-4% -$221K
PRQR icon
17
ProQR Therapeutics
PRQR
$327M
$5.4M 1.88%
1,460,000
-1,655,000
-53% -$2.17M
PHAT icon
18
Phathom Pharmaceuticals
PHAT
$723M
$4.68M 1.63%
+417,500
New +$4.3M
XOMA
19
DELISTED
Xoma
XOMA
$4.47M 1.55%
243,000
-5,000
-2% -$90.8K
CDXS icon
20
Codexis
CDXS
$182M
$4.46M 1.55%
957,500
-197,500
-17% -$1.08M
URGN icon
21
UroGen Pharma
URGN
$2.22B
$4.33M 1.51%
488,656
+91,156
+23% +$863K
KPTI icon
22
Karyopharm Therapeutics
KPTI
$44M
$4.28M 1.49%
+80,456
New +$5.58M
ATXS
23
DELISTED
Astria Therapeutics
ATXS
$3.9M 1.36%
261,703
+128,203
+96% +$1.32M
LQDA icon
24
Liquidia Corp
LQDA
$6.26B
$3.57M 1.24%
560,000
-3,500
-0.6% -$18.8K
ZNTL icon
25
Zentalis Pharmaceuticals
ZNTL
$367M
$3.37M 1.17%
+167,500
New +$3.6M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2022 Portfolio in Review

As of Q4 2022, Opaleye Management held 53 positions worth $288M, up 19% from $242M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management deployed $18.1M of net new capital in Q4 2022, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was Biohaven: 540,000 shares worth $7.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $3.89M trimmed.

  • Opaleye Management's largest Q4 2022 buy was Biohaven: 540,000 shares worth $7.5M.
  • Opaleye Management added most to Harrow in Q4 2022, an estimated $5.15M increase.
  • Opaleye Management's biggest Q4 2022 reduction was Keros Therapeutics, cutting an estimated $3.89M.
  • Opaleye Management fully exited Cutera, Inc. in Q4 2022, selling an estimated $6.74M.
  • Opaleye Management's ten largest holdings make up 62% of its $288M portfolio in Q4 2022.
  • Opaleye Management opened 11 new positions and closed 13 in Q4 2022.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $288M.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.